Posted by Defense World Staff on Apr 30th, 2024
Signaturefd LLC grew its position in shares of Enovis Co. (NYSE:ENOV – Free Report) by 197.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,257 shares of the company’s stock after purchasing an additional 1,498 shares during the quarter. Signaturefd LLC’s holdings in Enovis were worth $126,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Enovis by 12.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,086 shares of the company’s stock worth $565,000 after purchasing an additional 1,100 shares in the last quarter. Louisiana State Employees Retirement System purchased a new position in shares of Enovis during the 4th quarter valued at approximately $784,000. Lawson Kroeker Investment Management Inc. NE acquired a new stake in Enovis in the 4th quarter valued at $7,013,000. Allspring Global Investments Holdings LLC lifted its stake in Enovis by 0.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,031,710 shares of the company’s stock valued at $57,796,000 after buying an additional 4,274 shares in the last quarter. Finally, SeaBridge Investment Advisors LLC acquired a new stake in Enovis in the 4th quarter worth about $469,000. 98.45% of the stock is owned by hedge funds and other institutional investors.
Enovis Price Performance
Shares of ENOV opened at $55.89 on Tuesday. Enovis Co. has a 1-year low of $43.04 and a 1-year high of $66.14. The stock has a market cap of $3.07 billion, a PE ratio of -91.62 and a beta of 1.97. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.43 and a quick ratio of 1.16. The firm has a 50-day simple moving average of $59.80 and a two-hundred day simple moving average of $55.65.
Enovis (NYSE:ENOV – Get Free Report) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.76 by $0.03. The firm had revenue of $455.00 million during the quarter, compared to analysts’ expectations of $444.34 million. Enovis had a negative net margin of 1.95% and a positive return on equity of 3.84%. Enovis’s quarterly revenue was up 11.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.72 earnings per share. As a group, analysts forecast that Enovis Co. will post 2.58 EPS for the current year.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the company. Stephens initiated coverage on Enovis in a research report on Tuesday, February 13th. They issued an “overweight” rating and a $72.00 target price on the stock. Canaccord Genuity Group lifted their target price on shares of Enovis from $73.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $82.00 target price on shares of Enovis in a research report on Wednesday, April 10th. UBS Group started coverage on shares of Enovis in a research note on Monday, January 22nd. They issued a “buy” rating and a $75.00 target price on the stock. Finally, Wells Fargo & Company upped their price target on Enovis from $73.00 to $79.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Enovis presently has an average rating of “Buy” and an average target price of $75.43.
View Our Latest Stock Report on ENOV
Enovis Company Profile
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
See Also
- Five stocks we like better than Enovis
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- The 3 Hottest Insiders Buys This Month
- 5 discounted opportunities for dividend growth investors
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- How to Invest in the FAANG Stocks
- Microsoft Analysis: Trends, Predictions & Investment Insight
Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Co. (NYSE:ENOV – Free Report).
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
You might be interested in:
Mackenzie Financial Corp Acquires Shares of 2,267 American Woodmark Co.
Varex Imaging Co. Shares Sold by Mackenzie Financial Corp
Mackenzie Financial Corp Has $214,000 Position in Service Co. International
3,431 Shares in BlackLine, Inc. Bought by Mackenzie Financial Corp
Mackenzie Financial Corp Purchases Shares of 3,731 The Andersons, Inc.
Strs Ohio Acquires 4,600 Shares of J.Jill, Inc.